Back

Korea to cover Padcev-Keytruda first-line treatment from Oct. 1

Verifying
  • South Korea will reimburse combined Padcev-Keytruda therapy as first-line urothelial cancer treatment.
  • 31.5 months was median overall survival with combination therapy versus 16.1 months for conventional chemotherapy.
  • Coverage also expands to Retevmo capsules and Vyloy injection from Oct. 1.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Korea to cover Padcev-Keytruda first-line treatment from Oct. 1 - CoinPost Terminal